BAMCO Inc’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-197,980
Closed -$27.3M – 433
2021
Q4
$27.3M Buy
197,980
+85,463
+76% +$10.9M 0.06% 230
2021
Q3
$15.6M Sell
112,517
-33,483
-23% -$4.18M 0.04% 275
2021
Q2
$14.2M Hold
146,000
– – 0.03% 277
2021
Q1
$9.98M Sell
146,000
-12,675
-8% -$1.03M 0.02% 289
2020
Q4
$13.6M Buy
158,675
+4,400
+3% +$373K 0.03% 257
2020
Q3
$10M Buy
154,275
+2,900
+2% +$190K 0.03% 247
2020
Q2
$11.1M Hold
151,375
– – 0.04% 218
2020
Q1
$5.15M Buy
151,375
+147,075
+3,420% +$6.72M 0.03% 238
2019
Q4
$234K Buy
+4,300
New +$213K ﹤0.01% 314

Other funds holding BHVN

BAMCO Inc's BHVN Position: Q1 2022 in Review

BAMCO Inc sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 197,980 shares — an estimated $27.3M sold.

BAMCO Inc first reported a position in BHVN in Q4 2019 and held it in 9 quarters. The position peaked at $27.3M in Q4 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

  • BAMCO Inc reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
  • BAMCO Inc sold 197,980 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $27.3M.
  • BAMCO Inc first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 9 quarters.
  • BAMCO Inc's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $27.3M in Q4 2021.
  • 307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on BAMCO Inc's 13F filing for Q1 2022, filed 13 May 2022.